Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Atsuko Ogino, Ph.D., M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Eser PÖ, Paranal RM, Son J, Ivanova E, Kuang Y, Haikala HM, To C, Okoro JJ, Dholakia KH, Choi J, Eum Y, Ogino A, Missios P, Ercan D, Xu M, Poitras MJ, Wang S, Ngo K, Dills M, Yanagita M, Lopez T, Lin M, Tsai J, Floch N, Chambers ES, Heng J, Anjum R, Santucci AD, Michael K, Schuller AG, Cross D, Smith PD, Oxnard GR, Barbie DA, Sholl LM, Bahcall M, Palakurthi S, Gokhale PC, Paweletz CP, Daley GQ, Jänne PA. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738. PMID: 34516823.
    Citations:    Fields:    
  2. Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, Ambrogio C, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Jänne PA. ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. Mol Cancer Ther. 2021 04; 20(4):641-654. PMID: 33536188.
    Citations: 1     Fields:    
  3. Ogino A, Choi J, Lin M, Wilkens MK, Calles A, Xu M, Adeni AE, Chambers ES, Capelletti M, Butaney M, Gray NS, Gokhale PC, Palakurthi S, Kirschmeier P, Oxnard GR, Sholl LM, Jänne PA. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Mol Oncol. 2021 01; 15(1):27-42. PMID: 32191822.
    Citations: 1     Fields:    
  4. Sato H, Ogino A, Matsuzaka S, Asami Y, Kanbayashi S, Masuda M, Nakashima A, Yasuda M, Morishita H, Ando Y, Oida K, Taguchi N, Hirose M. Ovarian abscess caused by Helicobacter cinaedi in a patient with endometriosis. IDCases. 2019; 17:e00578. PMID: 31309037.
  5. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 05 15; 77(10):2712-2721. PMID: 28363995.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  6. Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer Discov. 2015 Sep; 5(9):960-971. PMID: 26036643.
    Citations: 78     Fields:    Translation:HumansAnimalsCells
  7. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013 Aug 15; 19(16):4532-40. PMID: 23833300.
    Citations: 101     Fields:    Translation:Humans
  8. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011 Sep 15; 71(18):6051-60. PMID: 21791641.
    Citations: 230     Fields:    Translation:HumansCells
  9. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012 Feb; 75(2):161-6. PMID: 21767894.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  10. Sawada S, Yamashita M, Komori E, Suehiro H, Ogino A, Nogami H, Segawa Y, Shinkai T. [Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment]. Gan To Kagaku Ryoho. 2010 Mar; 37(3):439-42. PMID: 20332679.
    Citations:    Fields:    Translation:Humans
  11. Ichihara E, Ohashi K, Takigawa N, Osawa M, Ogino A, Tanimoto M, Kiura K. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res. 2009 Jun 15; 69(12):5091-8. PMID: 19491268.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  12. Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, Kato Y, Ogino A, Komori E, Sawada S, Yamashita M, Nishimura R, Teramoto N, Takashima S. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol. 2009 Aug; 135(8):1055-9. PMID: 19152002.
    Citations: 11     Fields:    Translation:HumansCells
  13. Ogino A, Shinkai T. [Intrapleural chemotherapy--current status and problems in Japan]. Gan To Kagaku Ryoho. 2008 Jun; 35(6):896-9. PMID: 18633216.
    Citations:    Fields:    Translation:Humans
  14. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K, Tanimoto M. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007 Aug 15; 67(16):7807-14. PMID: 17699786.
    Citations: 71     Fields:    Translation:HumansCells
  15. Toyooka S, Uchida A, Shigematsu H, Soh J, Ogino A, Takata M, Kiura K, Ouchida M, Kosaka T, Aoe M, Mitsudomi T, Date H. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. J Thorac Oncol. 2007 Apr; 2(4):321-4. PMID: 17409805.
    Citations:    Fields:    Translation:HumansCells
  16. Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, Takigawa N, Tabata M, Takata M, Kiura K, Tanimoto M. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007 Mar; 98(3):357-63. PMID: 17270025.
    Citations: 14     Fields:    Translation:HumansCells
  17. Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M. Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Am J Hematol. 2006 May; 81(5):349-54. PMID: 16628731.
    Citations: 3     Fields:    Translation:Humans
  18. Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, Uchida A, Bessho A, Segawa Y, Shinkai T, Nogami N, Harita S, Okimoto N, Ueoka H, Tanimoto M. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res. 2005 May-Jun; 25(3c):2429-34. PMID: 16080470.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  19. Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Tanimoto M. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol. 2005; 44(7):717-22. PMID: 16227162.
    Citations: 11     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ogino's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (107)
Co-Authors (23)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.